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IMPORTANCE To date, there is no diagnostic test for Kawasaki disease (KD). Diagnosis is
based on clinical features shared with other febrile conditions, frequently resulting in delayed
or missed treatment and an increased risk of coronary artery aneurysms.
OBJECTIVE To identify a whole-blood gene expression signature that distinguishes children
with KD in the first week of illness from other febrile conditions.
DESIGN, SETTING, AND PARTICIPANTS The case-control study comprised a discovery group
that included a training and test set and a validation group of children with KD or comparator
febrile illness. The setting was pediatric centers in the United Kingdom, Spain, the
Netherlands, and the United States. The training and test discovery group comprised
404 children with infectious and inflammatory conditions (78 KD, 84 other inflammatory
diseases, and 242 bacterial or viral infections) and 55 healthy controls. The independent
validation group comprised 102 patients with KD, including 72 in the first 7 days of illness, and
130 febrile controls. The study dates were March 1, 2009, to November 14, 2013, and data
analysis took place from January 1, 2015, to December 31, 2017.
MAIN OUTCOMES ANDMEASURES Whole-blood gene expressionwas evaluated using
microarrays, andminimal transcript sets distinguishing KDwere identified using a novel
variable selectionmethod (parallel regularized regressionmodel search). The ability of
transcript signatures (implemented as disease risk scores) to discriminate KD cases from
controls was assessed by area under the curve (AUC), sensitivity, and specificity at the
optimal cut point according to the Youden index.
RESULTS Among 404 patients in the discovery set, there were 78 with KD (median age,
27 months; 55.1%male) and 326 febrile controls (median age, 37 months; 56.4%male).
Among 202 patients in the validation set, there were 72 with KD (median age, 34months;
62.5%male) and 130 febrile controls (median age, 17 months; 56.9%male). A 13-transcript
signature identified in the discovery training set distinguished KD from other infectious and
inflammatory conditions in the discovery test set, with AUC of 96.2% (95% CI,
92.5%-99.9%), sensitivity of 81.7% (95% CI, 60.0%-94.8%), and specificity of 92.1%
(95% CI, 84.0%-97.0%). In the validation set, the signature distinguished KD from febrile
controls, with AUC of 94.6% (95% CI, 91.3%-98.0%), sensitivity of 85.9% (95% CI,
76.8%-92.6%), and specificity of 89.1% (95% CI, 83.0%-93.7%). The signature was applied
to clinically defined categories of definite, highly probable, and possible KD, resulting in AUCs
of 98.1% (95% CI, 94.5%-100%), 96.3% (95% CI, 93.3%-99.4%), and 70.0% (95% CI,
53.4%-86.6%), respectively, mirroring certainty of clinical diagnosis.
CONCLUSIONS AND RELEVANCE In this study, a 13-transcript blood gene expression signature
distinguished KD from other febrile conditions. Diagnostic accuracy increased with certainty
of clinical diagnosis. A test incorporating the 13-transcript disease risk score may enable
earlier diagnosis and treatment of KD and reduce inappropriate treatment in those with other
diagnoses.
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K
awasaki disease (KD) is an acute inflammatory disor-
derpredominantly seen inyoungchildren. Since itwas
first described in Japan,1 KD has emerged as the most
common cause of acquired heart disease, with an incidence
in children younger than 5 years ranging from 265 cases per
100000 inJapan,2 to51 to 194casesper 100000 inotherAsian
countries,3-5 to 8 to 20 cases per 100000 in Europe6 and the
United States,7 respectively. Whatmakes KD of such concern
is its associationwith vasculitis, affecting predominantly the
coronary arteries, which results in coronary artery aneu-
rysms (CAAs) in up to 25%of untreated children.8Death from
myocardial infarction may occur due to thrombotic occlu-
sion of the aneurysms or from the later development of ste-
notic lesions due to vascular remodeling in the damaged
artery. Long-term outcome studies9,10 of children with giant
CAAs indicate a worrisome prognosis, with more than 50%
needing revascularization or experiencing myocardial in-
farction within a 30-year period.
Treatmentwithintravenousimmunoglobulin(IVIG)and,for
those who do not respond, additional IVIG11 or other anti-
inflammatoryagents, suchas corticosteroids and infliximab, is
effective in abrogating the inflammatory process and reduces
the risk of CAAs to 5% to 10%.12 Because KD is difficult to dis-
tinguish from other common febrile conditions, many chil-
dren with KD are not diagnosed and treated early enough to
preventdevelopmentofCAAs.13Furthermore,patientswhodo
not fulfill the clinical criteria for diagnosing KD (so-called
incomplete KD) may experience CAAs. Delayed diagnosis
is a consistent risk factor for development of CAAs, and treat-
ment is often commenced only when coronary dilatation is
already demonstrated on echocardiography.
The symptoms of KD are similar to those of several other
childhood febrile illnesses, includingstaphylococcal andstrep-
tococcal toxic shock syndromes, measles and other viral ill-
nesses (eg, adenovirus infection, Rocky Mountain spotted
fever), and childhood inflammatorydiseases, leading todiag-
nostic difficulty and thus delay in diagnosis and treatment.
Guidelines have been developed to facilitate diagnosis based
on clinical signs and symptoms, echocardiography, and labo-
ratory variables,14 but there remains an urgent need for an
accurate test to distinguishKD fromother conditions causing
prolonged fever in children.
In the era of precisionmedicine, diagnosis ofmany condi-
tions previously based on clinical features alone is being re-
placed bydiagnosis based onmolecular pathology.Host blood
gene expression signatures have been shown to identify sev-
eral specific infectious and inflammatory diseases, including
tuberculosis,15 bacterial and viral infections,16,17 and systemic
lupuserythematosus.18Support foradiagnosticapproachtoKD
based on gene expression signatures comes from identifica-
tionofmicroRNAbiomarkers inKD,19,20althoughexistingstud-
ies are limited by the range of comparator patients or a need to
extract RNA from exosomes. We explored use of whole-blood
gene expression patterns to distinguish KD from other child-
hoodinfectiousandinflammatoryconditions.Wepresentagene
expression signature, discovered and validated in indepen-
dent patient groups, that distinguishes KD from a range of
bacterial, viral, and inflammatory illnesses.
Methods
Ethical Approval and Informed Consent
Patientswererecruited,withwrittenparental informedconsent,
underapprovalsbytheresearchethicscommitteesof theUnited
Kingdom(StMary’sHospital09/H0712/58, 13/LO/0026); Spain
(Ethical Committee of Clinical Investigation of Galicia [CEIC]
2010/015); Amsterdam, the Netherlands (NL41023.018.12 and
NL34230.018.10); and the University of California San Diego
(HumanResearch Protection Program 140220).
Patient Study Groups
ThedifferentialdiagnosisforKDincludesmultiple infectiousand
inflammatoryconditions.Therefore, in this case-control study,
weestablishedadiscoverygroupofchildrenwithKDandarange
ofother infectiousandinflammatorydiseaseswithclinicalsigns,
inflammatorymarkers,anddurationoffeveroverlappingKD.Pa-
tients were prospectively recruited at pediatric centers in the
UnitedKingdom,Spain, theNetherlands, and theUnitedStates
if theyhad febrile illness and requiredblood testing for clinical
investigationaspart of theUK-based ImmunopathologyofRe-
spiratory, Inflammatory and Infectious Disease Study (IRIS)17;
theSpanishGENDRES (Genetic,VitaminD, andRespiratory In-
fectionsResearchNetwork)study(http://www.gendres.org); the
Dutch Kawasaki Study; or the US-based Kawasaki Disease
Research Center Program (https://medschool.ucsd.edu/som
/pediatrics/research/centers/kawasaki-disease).Thetrainingand
testdiscoverygroupcomprised404childrenwithinfectiousand
inflammatory conditions (78 KD, 84 other inflammatory
diseases, and 242 bacterial or viral infections) and 55 healthy
controls. The independent validation group comprised 102
patientswith KD, including 72 in the first 7 days of illness, and
130 febrile controls. The study dates were March 1, 2009, to
November 14, 2013, and data analysis took place from January
1, 2015, to December 31, 2017.
ChildrenwithKD representeda combinationof those seen
directly in emergency departments andpatients referred from
regional centers.Ourstudy includedonlypatients recruitedbe-
fore initiationof IVIG for treatment.Fordiscoveryof adiagnos-
tic signature,we includedpatientswithKD in the first 7daysof
illnessbecauseweaimedtodevelopa test foruseearly in the ill-
nessbeforecoronaryarterydamageoccurs.However, toexplore
Key Points
Question Can Kawasaki disease be accurately diagnosed on the
basis of the pattern of host gene expression in whole blood?
Findings In this case-control study of 606 children (404 in the
discovery cohort; 202 in the validation cohort), a 13-transcript
signature was identified that accurately discriminated Kawasaki
disease from comparator febrile diseases in discovery and
validation cohorts.
Meaning A diagnostic blood test based onmeasurement of small
numbers of host gene transcripts might enable early
discrimination of Kawasaki disease from other infectious and
inflammatory conditions.
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the performance of the signature at all stages of illness, we in-
cludedpatientsuptoday10oftheir illnessinthevalidationstudy.
Febrile controls whose duration of illness before hospital
presentation varied were recruited, with blood samples col-
lected as soon as possible after presentation and before clini-
cal diagnosis was confirmed. Febrile controls were assigned to
diagnostic groups using predefined criteria once the results of
all investigations were available (Figure 1 and eMethods in the
Supplement). Children with comorbidities likely to influence
gene expression, such as immunosuppressive treatments,
were excluded. We included comparator groups of children
seen with inflammatory illness, including juvenile idiopathic
arthritis and Henoch-Schönlein purpura. Comparison of the
duration of illness, inflammatory markers. and demographics
between patients with KD and febrile controls is summarized
in Table 1.
Patients in the validation study group were similarly
recruitedaspartofbiomarker studiesof febrile childrenseen in
thehospitalandrequiringbloodtests,asdescribedpreviously.21,22
Healthy control childrenwith no recent history of fever or im-
munizationwere recruited alongside patients with KD and fe-
brilecontrolpatientsinthediscoveryandvalidationstudies.Data
fromhealthycontrolswereusedtostandardizedataobtained in
differentmicroarrayexperimentsbutwerenotusedtoevaluate
the performance of the signature.
KD Case Definition
Kawasaki disease was diagnosed on the basis of the Ameri-
can Heart Association criteria,14 with 2-dimensional echo-
cardiography performed soon after presentation (2 and 6
weeks after onset). Patients with fewer than 4 of the 5 clas-
sic criteria (bilateral nonpurulent conjunctivitis, oral muco-
sal changes, peripheral extremity changes, rash, and cervi-
cal lymphadenopathy >1.5 cm) were included as having
incomplete KD if the maximum coronary artery z score
(Zmax) (standard deviation units from the mean internal
diameter normalized for body surface area) at any time dur-
ing the illness for the left anterior descending or right coro-
nary arteries was 2.5 or higher or if the patients satisfied the
algorithm for incomplete KD in the American Heart Associa-
tion guidelines. Patients were classified as having normal
(Zmax <2.5), small (Zmax 2.5 to <5.0), or large (Zmax ≥5.0)
CAAs. Because of interoperator variability in coronary
artery dimensions, we set a high (Zmax ≥5.0) threshold to
define patients with confirmed aneurysms and thus definite
diagnosis of KD.
Figure 1. Assignment of Patients to Diagnostic Groups
Patient recruitment and sample collection:
whole blood collected from patient with febrile illness
Review clinical investigation results, including
bacteriology, virology, radiology, hematology and chemistry
Categorization of patient based on clinical data
Inflammatory syndromes
Inflammatory syndrome not
   responding to antibiotics
Not explained by pathogen
Matches diagnostic criteria
Probable or
definite KD
matched to
AHA
criteria
Sterile site
pathogenic
bacteria and
matching
syndrome
Other
inflammatory
syndromes
(JIA and HSP)
Bacterial
syndrome
but no
bacteria
identified
Inconclusive
features or
microbiology
does not fit
syndrome
Viral 
syndrome
but no
virus
identified
Virus
identified
that
matches
syndrome
CRP ≤60 mg/L
and
neutrophils
≤12 000/µL
KD with CAA
KD without CAA
Bacterial symptoms
Sepsis/suspected sepsis
Focal pyogenic infection
Focal pneumonia
Empyema
Meningitis (with polymorphs)
Bone infection
Urinary tract
Viral symptoms
Febrile illness without
   localizing features
Flulike illness
Meningitis
   (with lymphocytes)
Respiratory illness without
   consolidation or empyema
Healthy control
No recent infection
Not recently immunized
Definite
viral
Uncertain
bacterial or viral
Definite
bacterial
Healthy
control
YesNo
The diagnostic algorithm demonstrates themethod of assigning patients to diagnostic groups. AHA indicates American Heart Association; CAA, coronary artery
aneurysm; CRP, C-reactive protein; HSP, Henoch-Schönlein purpura; JIA, juvenile idiopathic arthritis; and KD, Kawasaki disease. To convert C-reactive protein level to
nanomoles per liter, multiply by 9.524; to convert neutrophil count to ×109/L, multiply by 0.001.
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Further Classification of KD by Diagnostic Certainty
Because there is no gold standard for diagnosis, some pa-
tientsmaymeet the criteria for KDbut have other conditions.
Therefore,we further categorizedpatientswithKD in thevali-
dation studygroupbasedoncertaintyof clinical diagnosis. All
clinical records, laboratory results, echocardiogram reports,
response to treatment, and follow-upwere reviewedby an in-
dependent pediatric infectious disease specialist and expert
on KD (M.P.G.) masked to the analysis. Patients with docu-
mentedCAAs (Zmax≥5.0) persisting6weeks after onsetwere
consideredtohavedefiniteKDbecause there isnootherknown
self-resolving inflammatory illness in childhood that leads to
CAAs. The remaining patients (all of whomwere treatedwith
IVIG for suspected KD) were classified as having highly prob-
able, possible, or unlikely KD by the expert reviewer. This re-
view identified no unlikely KD cases.
Febrile Control Children
With Infection or Other Inflammatory Syndromes
Children seen with febrile illnesses were recorded as having
definite bacterial infection, definite viral infection, sus-
pected bacterial or viral infection, juvenile idiopathic arthri-
tis,orHenoch-Schönleinpurpura.ThecriteriashowninFigure1
and described in eMethods in the Supplement were used to
make this determination.
Oversight and Conduct of the Study
Patients were categorized into disease groups (Figure 1) after
evaluation of all results by 2 independent clinicians not in-
volved in thepatients’ care (J.A.H., A.M.B., J.T.K.,M.P.G., and
J.C.B.). All blood samples were anonymized, and transcrip-
tomic data sets were analyzed only after clinical assignments
were finalized and dispatched for independent verification
(eMethods in the Supplement).
Discovery and Validation of the Gene Expression Signature
The overall study design and signature discovery pipeline
are shown in Figure 2. Whole blood was collected at
the time of recruitment into blood RNA tubes (PAXgene;
PreAnalytiX), frozen, extracted, and analyzed on arrays
(HumanHT-12 version 4.0 BeadChip; Illumina). An earlier
array (HumanHT-12 version 3.0 BeadChip; Illumina) with
Table 1. Clinical Characteristics and Initial Laboratory Values for PatientsWith Kawasaki Disease and Febrile Controls
in Discovery and Validation Study Groupsa
Variable
Discovery Set Validation Set
Kawasaki Disease Febrile Controlsb Kawasaki Diseasec Febrile Controlsb
No. of patients 78 326 72 130
Age, median (IQR), mo 27 (16 to 45) 37 (9 to 116) 34 (17 to 51) 17 (5 to 47)
Male sex, No. (%) 43 (55.1) 184 (56.4) 45 (62.5) 74 (56.9)
Illness day at sample collection,
median (IQR)d
5 (4 to 6) 6 (4 to 9) 5 (5 to 6) 5 (3 to 7)
Laboratory values, median (IQR)
Hemoglobin z scoree −1.3 (−2.0 to −0.3) NA −1.2 (−2.0 to −0.4) NA
C-reactive protein, mg/L 119 (48 to 192) 66 (23 to 174) 87 (59 to 173) 62 (16 to 162)
Platelet count, ×103/μL 352 (303 to 448) 254 (167 to 351) 408 (324 to 474) 277 (176 to 352)
White blood cell count, /μL 14 200 (10 400 to 18 300) 8000 (6000 to 12 900) 13 900 (11 000 to 19 000) 11 000 (7700 to 16000)
Neutrophil count, /μL 9000 (6600 to 12400) 5000 (3100 to 9400) 10000 (7300 to 12600) 7000 (3600 to 13400)
Ethnicity, No. (%)
No. not statedf 0 23 (7.1) 0 10 (8.3)
African 3 (3.8) 28 (8.6) 2 (2.8) 23 (19.2)
Asian, including Indian
subcontinent and Far East
12 (15.4) 29 (8.9) 12 (16.7) 12 (10.0)
European 20 (25.6) 186 (57.1) 20 (27.8) 68 (56.7)
Hispanic 25 (32.1) 20 (6.1) 14 (19.4) 0
Mixed 15 (19.2) 28 (8.6) 23 (31.9) 7 (5.8)
Other 3 (3.8) 12 (3.7) 1 (1.4) 10 (8.3)
Coronary artery status, No. (%)
Normal 45 (57.7) NA 52 (72.2) NA
Dilated 25 (32.1) NA 15 (20.8) NA
Aneurysm 8 (10.3) NA 5 (6.9) NA
IVIG resistant, No. (%) 18 (23.1) NA 15 (20.8) NA
Abbreviations: IQR, interquartile range; IVIG, intravenous immunoglobulin;
NA, not applicable.
SI conversation factors: To convert C-reactive protein level to nanomoles per
liter, multiply by 9.524; neutrophil count to ×109/L, multiply by 0.001;
platelet count to ×109/L, multiply by 1.0; and white blood cell count to ×109/L,
multiply by 0.001.
a There were no significant differences between patients with Kawasaki disease
in the discovery and validation sets.
bHealthy controls were not included.
c Data refer to the 72 patients in the first week of Kawasaki disease.
d Illness day 1 is the first day of fever (in Kawasaki disease) or symptoms
(in febrile controls).
eHemoglobin was normalized by age (data unavailable for febrile controls).
f Ethnicity percentages were calculated for the denominator with recorded
data.
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largely overlapping probes was used in a subset of the vali-
dation study group. Details of laboratory methods are pro-
vided in eMethods in the Supplement.
Statistical Analysis
Transcript Signature Discovery
Analysis of the transcriptomic data was conducted with sta-
tistical software (R, version 3.2.2; RFoundation for Statistical
Computing). As shown in Figure 2, the discovery study group
was randomly divided into an 80% training set and a 20%
test set. The signature was identified in the training set and
validated in the test set and in the validation study group, es-
tablishedusingpreviously reportedacuteandconvalescentpa-
tients with KD21 and acute bacterial and viral patients22
(eMethods in the Supplement). After quality control and
filtering (eMethods in the Supplement), significantly differ-
entially expressed transcripts in patients with KD compared
with all other diseases were identified in the training set.
Small Signature Discovery Using Parallel Regularized Regression
Model Search
A range of statistical methods are available to identify signa-
tures fromsignificantlydifferentiallyexpressed transcripts, in-
cluding least absolute shrinkage and selection operator
(LASSO)24 and elastic net.25 However, these approaches pro-
duce large signatures that may not be easy to translate into a
bedsidediagnostic test. Therefore,wedevelopedanovel vari-
able selection method, parallel regularized regression model
search, that identifies and ranks transcript signatures on the
basis of their least number of transcripts and highest accu-
racy in discrimination26 (eMethods in the Supplement). The
method first evaluates all possible 1- and 2-transcriptmodels
distinguishing KD from comparator diseases based on all sig-
nificantlydifferentiallyexpressed transcriptsandtakes the100
best-fitting 2-transcriptmodels to thenext round,whena fur-
ther transcript is added to themodel and all combinations are
again evaluated. The process continueswith the incremental
Figure 2. Study Design
Validation samples, including
version 3 arrays (n = 147) 
version 4 arrays (n = 233)
Data processingc: selection of
probes shared with version 3 arrays
and batch adjustment using ComBat
Discovery set samples
(n = 459)
Data quality control:
principal component analysis: 1 array excluded
Data processinga:
selection of probes shared with version 3 arrays
Sample selection and processinga:
RNA extraction, amplification, hybridization
on version 4 arrays (n = 459)
Training set (80%)
DB
(n = 41)
DV
(n = 76)
U
(n = 77)
JIA
(n = 52)
HSP
(n = 15)
KD
(n = 60)
HCb
(n = 43)
Test set (20%)
DB
(n = 11)
DV
(n = 18)
U
(n = 19)
JIA
(n = 14)
HSP
(n = 3)
KD
(n = 17)
HCb
(n = 12)
Validation set
DB
(n = 23)
DV
(n = 28)
U
(n = 79)
KDd
(n = 102)
HCe
(n = 103)
Determine SDE transcripts
with log2 FC ≥1
Use SDE transcripts to derive
minimal classifier using PReMSa
Febrile controls
Evaluate PReMS classifier:
apply to test set
Febrile controls
Evaluate PReMS classifier:
apply to validation set
Evaluate KD signature by clinical
diagnostic certainty
Febrile controls
The overall study pipeline shows sample handling, derivation of test and
training data sets, data processing, and analysis pipeline. Version 3 arrays
indicate HumanHT-12, version 3.0 BeadChip (Illumina); version 4 arrays indicate
HumanHT-12, version 4.0 BeadChip (Illumina); and ComBat indicates the
ComBat algorithm.23DB indicates definite bacterial; DV, definite viral; FC, fold
change; HC, healthy controls; HSP, Henoch-Schönlein purpura; JIA, juvenile
idiopathic arthritis; KD, Kawasaki disease; PReMS, parallel regularized
regressionmodel search; SDE, significantly differentially expressed; and U,
infections of uncertain bacterial or viral etiology.
a See Supplemental Methods (RNA sample extraction and processing), as well
as Statistical Methods in eMethods in the Supplement.
bHealthy controls were used in model building but were excluded from
estimates of model accuracy.
c See Statistical Methods in eMethods in the Supplement; 146 acute KD samples
(HumanHT-12, version 4.0) were used in Combat, of which 101 were taken
forward.
dDiagnostic performance was assessed on 72 patients (within the first 7 days of
illness).
e Includes convalescent KD and healthy controls.
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addition of 1 further transcript at a time to the best 100mod-
els. The optimal signature for a given number of transcripts
(model size) was selected after ranking each model by its
Watanabe-Akaike information criterion, which is a Bayesian
estimate of the out-of-sample error.27Theoptimalmodel size
was determined by cross-validation.
Disease Risk Score and Assessment ofModel Accuracy
We applied the previously reported disease risk score (DRS)
method that assigns individual disease risk based on the
transcripts in the diagnostic signature.15 The DRS combines
the fluorescence intensity of upregulated transcripts and
subtracts the combined fluorescence intensity of down-
regulated transcripts15 and might facilitate development of
tests from complex signatures. Healthy controls were used
in model building but were excluded from estimates of
model accuracy, assessed by area under the curve (AUC),
sensitivity, and specificity at the optimal cut point according
to the Youden index.
Results
The numbers of patients in each diagnostic category are
shown in Figure 2. Clinical and demographic features of
patients with KD and febrile controls are summarized in
Table 1, with further details of control patients listed in
eTable 1 in the Supplement. Principal component analysis of
the normalized transcript expression profiles was per-
formed separately on the discovery (training and test) and
validation groups (eFigure 1 and eFigure 2 in the Supple-
ment). Study groups clustered together in the discovery
group and in the validation group after combining KD and
case-control data using the ComBat algorithm23 (Statistical
Methods in eMethods in the Supplement).
Identification ofMinimal Transcript Signatures
In total, 1600 transcripts passed quality control and were
significantly differentially expressed between KD and all
other diseases and healthy controls (defined as log2 fold
change >1 in KD vs at least 1 of the comparator groups). To
identify small signatures suitable for developing as a
diagnostic test, we next undertook variable selection using
parallel regularized regression model search. This approach
identified a 13-transcript signature (Table 2) that, when
implemented as a DRS, had a diagnostic performance in the
discovery test set distinguishing KD from other infectious
and inflammatory conditions, with an AUC of 96.2%
(95% CI, 92.5%-99.9%), sensitivity of 81.7% (95% CI, 60.0%-
94.8%), and specificity of 92.1% (95% CI, 84.0%-97.0%)
(Figure 3A and B).
Signature Performance in Validation Set
When the signaturewas applied to all of the 72KDcases in the
validation set, whowere in the first 7 days of illness, the AUC
was 94.6% (95% CI, 91.3%-98.0%), with sensitivity of 85.9%
(95%CI,76.8%-92.6%)andspecificityof89.1%(95%CI,83.0%-
93.7%). The performance was slightly reduced in the 30 pa-
tients diagnosed later (days 8-10) (eTable 2 and eFigure 3 in
the Supplement).
Because clinical features of KD overlap those of other
conditions and because any KD study group is likely to
include patients misclassified as KD, we assessed whether
certainty of clinical diagnosis corresponded to the predictive
performance of the KD DRS. The performance of the
13-transcript signature in the patients with definite, highly
probable, or possible KD in the validation set mirrored cer-
tainty of clinical diagnosis, with AUCs of 98.1% (95% CI,
94.5%-100%), 96.3% (95% CI, 93.3%-99.4%), and 70.0%
(95% CI, 53.4%-86.6%), respectively (Figure 3C and D and
eTable 2 in the Supplement).
Table 2. Genes Included in the Diagnostic Signature
Gene Symbol Gene Name
HGNC
Identifi-
cation No.
Probe
Identification
No. Location
Logistic
Regression
Coefficienta
CACNA1E Calcium voltage-gated channel subunit
alpha1 E
1392 7510647 1q25.3 0.955
DDIAS DNA damage–induced apoptosis
suppressor
26351 2570019 11q14.1 0.844
KLHL2 Kelch-like family member 2 6353 1070593 4q32.3 0.789
PYROXD2 Pyridine nucleotide-disulphide
oxidoreductase domain 2
23517 1684497 10q24.2 0.727
SMOX Spermine oxidase 15862 270068 20p13 0.675
ZNF185 Zinc finger protein 185
with domain
12976 6840674 Xq28 0.646
LINC02035 Long intergenic non–protein
coding RNA 2035
52875 3236239 3q21.1 0.561
CLIC3 Chloride intracellular channel 3 2064 5870136 9q34.3 0.464
S100P S100 calcium-binding protein P 10504 1510424 4p16.1 −0.405
IFI27 Interferon alpha–inducible protein 27 5397 3990170 14q32.12 −0.426
HS.553068 BX103476 NCI_CGAP_Lu5
Homo sapiens cDNA clone
NA 1470450 NA −0.599
CD163 CD163 molecule 1631 2680092 12p13.31 −0.638
RTN1 Reticulon 1 10467 6860193 14q23.1 −0.690
Abbreviations:
cDNA, complementary DNA;
HGNC, Hugo Gene Nomenclature
Committee; NA, not applicable.
a The logistic regression coefficient
indicates the power of the gene to
discriminate Kawasaki disease in the
parallel regularized regression
model search. Genes with positive
values show increased expression in
Kawasaki disease relative to other
diseases, and genes with negative
values show decreased expression
in Kawasaki disease.
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Discussion
Weidentifieda13-transcriptsignaturethatdistinguishespatients
withKD frompatientswith bacterial, viral, and inflammatory
illnesses. Thehigh sensitivity and specificity of this signature
for early diagnosis of KD suggests that it might form the basis
of a diagnostic test. Our findings herein extendprevious gene
expressionstudies21,28-32 inKDthat focusedon immunopatho-
genesis.
The diagnosis of KD now relies on the presence of 4 of
the 5 characteristic clinical criteria. Fewer criteria are
accepted if coronary artery abnormalities (dilatation or
aneurysms) are detected on echocardiography. Children
with incomplete KD who do not fulfil the classic diagnostic
criteria but have prolonged fever and inflammation are at an
increased risk of developing CAAs.33 One reason for the
greater risk of CAAs in incomplete KD is the delayed diagno-
sis that often occurs in patients lacking all clinical features.
Because the clinical features of KD overlap those of many
other common childhood conditions,34 treatment with IVIG
may be delayed while awaiting exclusion of other condi-
tions. Conversely, because the diagnosis of KD is considered
in the differential diagnosis of many childhood febrile ill-
nesses and because the consequences of delayed treatment
may be severe, overtreatment with IVIG or immunosuppres-
sant second-line treatments may occur. A diagnostic test
that accurately distinguishes KD from other infectious and
inflammatory processes would be a significant advance in
management of the disorder, reduce unnecessary investiga-
tions and inappropriate treatments, and enable earlier treat-
ment with IVIG and other anti-inflammatory agents.
In establishing our discovery and validation study
groups, we aimed to include a wide range of disorders with
features overlapping those of KD, including both infectious
and inflammatory diseases. The signature that we have iden-
tified distinguished KD from a wide range of other conditions
with similar duration of fever and overlapping levels of
inflammation. Because KD is diagnosed based on a constella-
tion of clinical features and because there is no gold standard
for diagnosis, evaluation of biomarker test results is difficult.
Any cohort of children treated with IVIG for presumed KD is
likely to include some patients with non-KD illness but with
similar features. To evaluate the correspondence of the KD
DRS with levels of diagnostic certainty, we categorized
patients in the validation set as having definite, highly prob-
able, or possible KD based on independent review of the
clinical data. We observed a higher sensitivity and specificity
of our signature in the definite and highly probable KD
groups than in the possible KD group.
Figure 3. Performance of the 13-Transcript Signature on the Discovery Test Set and the Validation Set
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Regarding the transcripts in the signature (Table 2), ex-
pression was lower in patients with KD compared with the
non-KDgroup for 5 of the 13 transcripts. Of these, S100P, pre-
viously reported tohave increasedexpression inacuteKDrela-
tive to convalescence35orviral infections,32,35wasmost abun-
dant in patients with bacterial infection. The IFI27 gene has
been reported to be upregulated in children with viral com-
paredwithbacterial infections36andautoimmunediseases,37,38
consistent with reduced expression of genes induced by type
1 interferons reported in acute KD vs adenovirus infection.32
CD163 is a transmembrane receptor expressed in macro-
phages andmonocytes involved in bacterial clearance during
acute infection.39 A network analysis of the signature using
pathwayanalysis (IngenuityPathwaysAnalysis; IngenuitySys-
tems) revealed that 7of the 13 transcripts in the signaturewere
connected in a network around a central hub of tumor necro-
sis factor and interleukin 6 (eFigure 4 in the Supplement).
Strengths and Limitations
Werecognizeboth strengthsand limitations inour study.First,
theepidemiologyofKDvariesgloballybyethnicity.Althoughwe
includedpatientswithamixofethnicities inbothdiscoveryand
validationcohorts, further studies are required toestablish the
performanceof the signature in other geographic populations.
Second, in the validation experiment, data fromdifferent Illu-
minamicroarrayversionsandstudieswerecombinedusing the
ComBatalgorithmtoachievenormalization.Thisnormalization
mayreducebothexperimentalandbiologicalsourcesofvariabil-
ity between data sets; consequently, the accuracy (AUC) of the
signature in the validation set may be an underestimate. Con-
versely,althoughweshowedthattheComBatalgorithmsuccess-
fullynormalized thedata sets, residual batchassociationsmay
have falsely increased theperformanceof the signature.Third,
todevelopa signature applicable inawide rangeof febrile con-
ditions,wediscovered thesignature throughcomparisonofKD
cases with a wide range of febrile controls with a spectrum of
KD diagnosis likelihoods. This potentially biased the test
toward better discriminatory value than might be applicable
in the clinical setting. Fourth, we discovered the signature
using patients with KD in the first 7 days of illness, with the
aim of identifying a test for use early in the disease to enable
treatment before coronary injury has occurred. Because the
performance of the signature was lower in patients with KD
seen after the seventh day, further work is required to estab-
lish the optimal signature for diagnosis in patients with KD
with late presentation.
Conclusions
The results of our study suggest that KD can be distinguished
fromthe rangeof infectiousand inflammatoryconditionswith
which it isoftenclinicallyconfusedusing13transcripts inblood.
Development of a test based on this gene expression signature
ismademore achievable because of the small number of tran-
scripts in our signature and the rapidly evolving technologies
for detecting nucleic acids. A diagnostic test would be amajor
advanceallowingearlier treatment and thuspreventionof car-
diac complications of this serious childhooddisease. Our find-
ings represent a step toward better diagnosis of diseases based
onmolecular signatures rather than theclinical criteria andare
relevant tomany other clinical syndromes.
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